New update in kidney treatment
A drug called sparsentan has now received FDA approval for FSGS (Focal Segmental Glomerulosclerosis). This is important because FSGS is a condition where patients often have significant protein leak, and treatment options have been limited. Sparsentan works by targeting pathways involved in proteinuria reduction, and studies have shown it can help reduce protein leak in selected patients. But this is important ⚠️ Sparsentan (FSGS) — who is it for? Key cut-offs (from trials / approval context) - eGFR: generally ≥ 30 mL/min/1.73 m² - Proteinuria: significant protein leak (often UPCR ≥ 1.5 g/g) - Diagnosis: biopsy-proven primary FSGS (not secondary causes) What this means for you It’s a positive step forward in kidney care. But more importantly:Understanding your own reports (protein, eGFR, diagnosis) matters before thinking about treatments like this. New treatments are coming — which is good. But the basics still matter: - controlling BP - reducing protein leak - staying consistent Comment below - what do you think?